Amicus Therapeutics (FOLD) 주식
헬스케어 부문 기업. 10월 2026 기준 Amicus Therapeutics의 주가, 사업 개요, 알아두어야 할 핵심 정보를 정리했습니다.
Amicus Therapeutics (ticker FOLD) is a biopharmaceutical company focused on treatments for rare genetic diseases, notably Fabry disease. Its oral pharmacological chaperone, migalastat (marketed as Galafold), is approved in multiple regions and underpins current commercial revenue, while Amicus advances a pipeline that includes gene therapy and next‑generation small‑molecule programmes. Investors should note the blend of commercial execution (market uptake, reimbursement) and ongoing clinical and regulatory risk from trials and filings. Biotech stocks can be volatile around trial readouts, approvals, or partnership news, and valuation often reflects pipeline potential as much as current sales. With a market capitalisation around $2.61bn, Amicus sits between commercial and growth‑stage biotech. This is general educational information, not personalised advice; values can rise and fall and returns are not guaranteed, so consider your risk tolerance and conduct further research before investing.
Amicus Therapeutics (FOLD) 주식 전망
애널리스트 목표 주가, 향후 12개월
$15.63
+7.8% 오늘 $14.50 대비
최근 12개월 가격 범위
12개월 최고가에 근접
Amicus Therapeutics을(를) 담당하는 애널리스트들의 12개월 컨센서스 목표 주가는 $15.63으로, 현재가 $14.50 대비 높은 수준입니다.
애널리스트 목표 주가는 의견이며 보장이 아닙니다. 원금 손실 위험이 있습니다. 25 5월 2026 기준 데이터입니다.
출처: 애널리스트 심리 지표는 4만 곳 이상의 기업 고객을 보유한 글로벌 금융 시장 데이터 선두 기업 Refinitiv Ltd가 제공합니다. Refinitiv Ltd는 Nemo와 무관한 독립적인 제3자입니다. 본 내용은 투자 조언이 아닙니다.
6개월 성장 성과
주가 성과 요약
애널리스트 평가
Analysts recommend buying Amicus Therapeutics' stock with a target price of $15.63, indicating potential growth.
재무 건전성
Amicus Therapeutics has strong revenue and cash flow, indicating solid financial performance.
앱을 무료로 다운로드하고 더 많은 종목 보기
60초면 충분합니다.
FOLD이(가) 포함된 바스켓
Rare Kidney Disease Treatments | A Market Overview
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
게시일: 2026년 4월 14일
바스켓 살펴보기UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
게시일: 2025년 12월 2일
바스켓 살펴보기Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
게시일: 2025년 11월 17일
바스켓 살펴보기M&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
게시일: 2025년 11월 15일
바스켓 살펴보기Sanofi Dupixent Success Overview | Pharma Investment
Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
게시일: 2025년 10월 24일
바스켓 살펴보기Pharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
게시일: 2025년 10월 10일
바스켓 살펴보기Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
게시일: 2025년 8월 30일
바스켓 살펴보기Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
게시일: 2025년 8월 20일
바스켓 살펴보기Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
게시일: 2025년 7월 30일
바스켓 살펴보기이 종목을 주목해야 하는 이유
Specialist rare‑disease play
Amicus targets niche, high‑value patient populations where clinical impact can justify premium pricing, though market uptake and reimbursement remain uncertain.
Commercial + clinical mix
Galafold provides a commercial base while ongoing trials and regulatory milestones drive future value; clinical setbacks could have a big effect.
Pipeline and partnerships
Gene‑therapy work and potential collaborations can de‑risk programmes or accelerate reach, but such deals and outcomes are uncertain and may dilute investors.
왜 Nemo와 함께 투자해야 할까요?
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.
